Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Plant Diseases | 6 | 2020 | 57 | 3.740 |
Why?
|
Enterobacteriaceae | 9 | 2020 | 28 | 3.690 |
Why?
|
Quercus | 7 | 2020 | 8 | 3.500 |
Why?
|
RNA, Ribosomal, 16S | 12 | 2023 | 171 | 1.780 |
Why?
|
DNA, Bacterial | 7 | 2023 | 186 | 1.630 |
Why?
|
Tomography, X-Ray Computed | 5 | 2016 | 214 | 1.510 |
Why?
|
Fibrobacter | 4 | 2012 | 4 | 1.490 |
Why?
|
Gammaproteobacteria | 2 | 2020 | 6 | 1.470 |
Why?
|
Cellulose | 4 | 2014 | 14 | 1.410 |
Why?
|
Environmental Microbiology | 3 | 2014 | 26 | 1.380 |
Why?
|
Bacteria | 5 | 2017 | 255 | 1.360 |
Why?
|
Feces | 7 | 2020 | 111 | 1.310 |
Why?
|
Rahnella | 2 | 2019 | 3 | 1.290 |
Why?
|
Soil Microbiology | 4 | 2020 | 49 | 1.270 |
Why?
|
Radiology | 3 | 2017 | 10 | 1.210 |
Why?
|
Positron-Emission Tomography | 4 | 2017 | 80 | 1.170 |
Why?
|
Fungi | 4 | 2016 | 89 | 1.090 |
Why?
|
Nuclear Medicine | 2 | 2017 | 5 | 1.080 |
Why?
|
Fresh Water | 4 | 2016 | 48 | 1.060 |
Why?
|
Genomics | 2 | 2018 | 223 | 1.050 |
Why?
|
Multiple Myeloma | 4 | 2018 | 39 | 1.000 |
Why?
|
Sewage | 5 | 2023 | 19 | 0.950 |
Why?
|
Shellfish | 5 | 2017 | 13 | 0.950 |
Why?
|
Safety | 2 | 2014 | 48 | 0.920 |
Why?
|
Geologic Sediments | 5 | 2019 | 42 | 0.900 |
Why?
|
Ecology | 3 | 2020 | 22 | 0.900 |
Why?
|
Refuse Disposal | 4 | 2012 | 18 | 0.900 |
Why?
|
Water Microbiology | 6 | 2020 | 76 | 0.900 |
Why?
|
Lactobacillales | 1 | 2023 | 2 | 0.890 |
Why?
|
Trees | 2 | 2020 | 19 | 0.880 |
Why?
|
Environmental Monitoring | 5 | 2020 | 192 | 0.840 |
Why?
|
Fluorodeoxyglucose F18 | 4 | 2018 | 13 | 0.810 |
Why?
|
Food Contamination | 4 | 2017 | 55 | 0.790 |
Why?
|
Veterans | 1 | 2022 | 122 | 0.790 |
Why?
|
Rain | 1 | 2020 | 7 | 0.720 |
Why?
|
Radiopharmaceuticals | 2 | 2016 | 55 | 0.670 |
Why?
|
Enterovirus | 4 | 2020 | 7 | 0.670 |
Why?
|
Polymerase Chain Reaction | 6 | 2017 | 448 | 0.670 |
Why?
|
Phylogeny | 8 | 2023 | 644 | 0.670 |
Why?
|
RNA, Bacterial | 2 | 2016 | 33 | 0.640 |
Why?
|
Humans | 43 | 2022 | 37093 | 0.610 |
Why?
|
Sequence Analysis, DNA | 6 | 2023 | 474 | 0.600 |
Why?
|
Virulence Factors | 1 | 2018 | 113 | 0.580 |
Why?
|
Pseudomonadaceae | 1 | 2016 | 3 | 0.570 |
Why?
|
Internship and Residency | 2 | 2015 | 125 | 0.550 |
Why?
|
Neuroendocrine Cells | 1 | 2016 | 3 | 0.550 |
Why?
|
Somatostatin | 1 | 2016 | 22 | 0.550 |
Why?
|
Hyperplasia | 1 | 2016 | 38 | 0.540 |
Why?
|
Mouth | 1 | 2016 | 45 | 0.540 |
Why?
|
Radiation Dosage | 2 | 2014 | 37 | 0.540 |
Why?
|
Animals | 23 | 2020 | 15081 | 0.510 |
Why?
|
Lung Diseases | 1 | 2016 | 61 | 0.510 |
Why?
|
Fibroblasts | 2 | 2014 | 272 | 0.500 |
Why?
|
Certification | 1 | 2014 | 13 | 0.490 |
Why?
|
Internal Medicine | 1 | 2014 | 24 | 0.490 |
Why?
|
Radiation Injuries | 1 | 2014 | 22 | 0.480 |
Why?
|
Ichthyosis | 1 | 2014 | 4 | 0.480 |
Why?
|
Acantholysis | 1 | 2014 | 2 | 0.480 |
Why?
|
Chromosomes | 1 | 2014 | 37 | 0.470 |
Why?
|
Leukemia, Myeloid, Acute | 1 | 2014 | 30 | 0.460 |
Why?
|
Computers | 1 | 2013 | 35 | 0.460 |
Why?
|
Radioactive Hazard Release | 1 | 2013 | 6 | 0.460 |
Why?
|
Hypertension, Pulmonary | 1 | 2014 | 75 | 0.460 |
Why?
|
Shiga Toxin | 2 | 2010 | 5 | 0.450 |
Why?
|
Physician's Role | 1 | 2013 | 38 | 0.440 |
Why?
|
Guidelines as Topic | 1 | 2013 | 54 | 0.440 |
Why?
|
Mitosis | 1 | 2014 | 99 | 0.440 |
Why?
|
Bacteria, Anaerobic | 3 | 2023 | 10 | 0.430 |
Why?
|
Prostate | 1 | 2014 | 154 | 0.420 |
Why?
|
Disaster Planning | 1 | 2013 | 52 | 0.420 |
Why?
|
Microbiological Techniques | 1 | 2012 | 11 | 0.410 |
Why?
|
Decision Making | 1 | 2014 | 203 | 0.410 |
Why?
|
Software | 1 | 2013 | 217 | 0.410 |
Why?
|
Down-Regulation | 1 | 2014 | 435 | 0.410 |
Why?
|
Cooperative Behavior | 1 | 2013 | 219 | 0.400 |
Why?
|
Genetic Variation | 1 | 2014 | 387 | 0.400 |
Why?
|
RNA, Ribosomal, 18S | 2 | 2017 | 9 | 0.400 |
Why?
|
Escherichia coli | 4 | 2020 | 453 | 0.390 |
Why?
|
Gastrointestinal Tract | 1 | 2012 | 61 | 0.390 |
Why?
|
Response Elements | 1 | 2010 | 56 | 0.370 |
Why?
|
Coliphages | 1 | 2010 | 8 | 0.360 |
Why?
|
Prophages | 1 | 2010 | 4 | 0.360 |
Why?
|
Shiga-Toxigenic Escherichia coli | 1 | 2010 | 5 | 0.360 |
Why?
|
Virus Activation | 1 | 2010 | 35 | 0.360 |
Why?
|
Ecosystem | 3 | 2017 | 123 | 0.360 |
Why?
|
Dominance, Ocular | 1 | 2009 | 1 | 0.350 |
Why?
|
Diagnostic Techniques, Ophthalmological | 1 | 2009 | 14 | 0.350 |
Why?
|
NF-E2-Related Factor 2 | 1 | 2010 | 77 | 0.350 |
Why?
|
Trans-Activators | 1 | 2010 | 174 | 0.350 |
Why?
|
Sheep | 4 | 2016 | 72 | 0.340 |
Why?
|
Visual Perception | 1 | 2009 | 67 | 0.330 |
Why?
|
Bioreactors | 2 | 2023 | 21 | 0.320 |
Why?
|
Reactive Oxygen Species | 1 | 2010 | 461 | 0.310 |
Why?
|
Breast Neoplasms | 2 | 2017 | 1502 | 0.300 |
Why?
|
Transcription, Genetic | 1 | 2010 | 578 | 0.300 |
Why?
|
Antioxidants | 1 | 2010 | 416 | 0.290 |
Why?
|
Norovirus | 2 | 2017 | 10 | 0.290 |
Why?
|
Metagenomics | 3 | 2017 | 34 | 0.280 |
Why?
|
Middle Aged | 8 | 2018 | 10129 | 0.280 |
Why?
|
Genome, Bacterial | 2 | 2017 | 114 | 0.280 |
Why?
|
Prognosis | 3 | 2018 | 739 | 0.270 |
Why?
|
Sequence Analysis, RNA | 2 | 2018 | 106 | 0.270 |
Why?
|
Molecular Sequence Data | 5 | 2014 | 1568 | 0.260 |
Why?
|
Gene Expression Profiling | 4 | 2018 | 626 | 0.260 |
Why?
|
Radiation Protection | 1 | 2004 | 4 | 0.250 |
Why?
|
Equipment Failure | 1 | 2004 | 11 | 0.250 |
Why?
|
Radiometry | 1 | 2004 | 8 | 0.250 |
Why?
|
Radioactive Fallout | 1 | 2004 | 3 | 0.250 |
Why?
|
Gamma Rays | 1 | 2004 | 26 | 0.250 |
Why?
|
Equipment Failure Analysis | 1 | 2004 | 41 | 0.250 |
Why?
|
Contact Lenses, Extended-Wear | 1 | 2004 | 1 | 0.250 |
Why?
|
Ketorolac Tromethamine | 1 | 2004 | 2 | 0.250 |
Why?
|
Hyperopia | 1 | 2004 | 7 | 0.250 |
Why?
|
Salmonella | 2 | 2014 | 11 | 0.240 |
Why?
|
Seasons | 3 | 2019 | 112 | 0.240 |
Why?
|
DNA, Ribosomal | 3 | 2014 | 36 | 0.230 |
Why?
|
Cluster Analysis | 3 | 2017 | 195 | 0.230 |
Why?
|
Wales | 3 | 2020 | 4 | 0.230 |
Why?
|
DNA Primers | 4 | 2013 | 286 | 0.230 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2004 | 121 | 0.230 |
Why?
|
Base Composition | 1 | 2023 | 23 | 0.220 |
Why?
|
Pyruvates | 1 | 2023 | 6 | 0.220 |
Why?
|
Anaerobiosis | 1 | 2023 | 15 | 0.220 |
Why?
|
Bacterial Typing Techniques | 1 | 2023 | 34 | 0.220 |
Why?
|
Glycerol | 1 | 2023 | 28 | 0.220 |
Why?
|
Algorithms | 2 | 2017 | 465 | 0.220 |
Why?
|
Radiation, Ionizing | 2 | 2014 | 13 | 0.220 |
Why?
|
Rivers | 2 | 2021 | 44 | 0.210 |
Why?
|
Female | 11 | 2018 | 20969 | 0.210 |
Why?
|
Biodegradation, Environmental | 2 | 2013 | 80 | 0.210 |
Why?
|
Isoptera | 2 | 2012 | 5 | 0.210 |
Why?
|
Fatty Acids | 1 | 2023 | 127 | 0.200 |
Why?
|
Water Pollution | 2 | 2019 | 12 | 0.200 |
Why?
|
Male | 13 | 2018 | 20025 | 0.200 |
Why?
|
Rumen | 2 | 2012 | 5 | 0.190 |
Why?
|
Clostridium | 2 | 2012 | 21 | 0.190 |
Why?
|
Viruses | 1 | 2021 | 36 | 0.190 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 3 | 2012 | 623 | 0.190 |
Why?
|
Metagenome | 2 | 2017 | 29 | 0.190 |
Why?
|
beta-Lactamases | 1 | 2020 | 33 | 0.190 |
Why?
|
DNA Replication | 2 | 2014 | 152 | 0.180 |
Why?
|
Glioma | 2 | 2012 | 79 | 0.180 |
Why?
|
Neoplastic Stem Cells | 2 | 2012 | 78 | 0.180 |
Why?
|
Disease-Free Survival | 2 | 2018 | 113 | 0.180 |
Why?
|
Microbial Viability | 1 | 2020 | 37 | 0.180 |
Why?
|
Gastrointestinal Diseases | 1 | 2020 | 42 | 0.180 |
Why?
|
Plants | 1 | 2020 | 99 | 0.180 |
Why?
|
Delivery of Health Care | 1 | 2022 | 276 | 0.180 |
Why?
|
Fluorescent Antibody Technique | 2 | 2010 | 189 | 0.170 |
Why?
|
Arkansas | 3 | 2015 | 39 | 0.170 |
Why?
|
Species Specificity | 1 | 2020 | 245 | 0.170 |
Why?
|
Visual Acuity | 3 | 2012 | 97 | 0.170 |
Why?
|
Adenoviruses, Human | 1 | 2018 | 2 | 0.170 |
Why?
|
Spleen | 2 | 2017 | 199 | 0.160 |
Why?
|
Diffusion Magnetic Resonance Imaging | 1 | 2018 | 17 | 0.160 |
Why?
|
Temperature | 2 | 2021 | 286 | 0.160 |
Why?
|
Water Purification | 1 | 2018 | 28 | 0.160 |
Why?
|
Waste Disposal, Fluid | 1 | 2018 | 14 | 0.160 |
Why?
|
Systems Biology | 1 | 2017 | 22 | 0.150 |
Why?
|
Genome, Plant | 1 | 2017 | 27 | 0.150 |
Why?
|
Droughts | 1 | 2017 | 21 | 0.150 |
Why?
|
Necrosis | 1 | 2017 | 49 | 0.150 |
Why?
|
Enterovirus Infections | 1 | 2017 | 4 | 0.150 |
Why?
|
Hexokinase | 1 | 2017 | 10 | 0.150 |
Why?
|
Reagent Kits, Diagnostic | 1 | 2017 | 12 | 0.150 |
Why?
|
Caliciviridae Infections | 1 | 2017 | 7 | 0.150 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 1 | 2017 | 19 | 0.150 |
Why?
|
Mytilus edulis | 1 | 2016 | 1 | 0.140 |
Why?
|
Biodiversity | 1 | 2017 | 83 | 0.140 |
Why?
|
Medicine | 1 | 2017 | 33 | 0.140 |
Why?
|
DNA Gyrase | 1 | 2016 | 7 | 0.140 |
Why?
|
Aged | 3 | 2018 | 6741 | 0.140 |
Why?
|
England | 1 | 2016 | 12 | 0.140 |
Why?
|
Communicable Diseases | 1 | 2017 | 45 | 0.140 |
Why?
|
DNA, Fungal | 1 | 2016 | 46 | 0.140 |
Why?
|
Anti-Bacterial Agents | 2 | 2010 | 352 | 0.140 |
Why?
|
Carbon | 1 | 2017 | 105 | 0.140 |
Why?
|
Carcinoma, Lewis Lung | 2 | 2013 | 6 | 0.140 |
Why?
|
Enterococcus | 1 | 2016 | 6 | 0.140 |
Why?
|
Bone Marrow Cells | 2 | 2014 | 81 | 0.140 |
Why?
|
Glycolysis | 1 | 2016 | 68 | 0.140 |
Why?
|
Host-Pathogen Interactions | 1 | 2018 | 186 | 0.140 |
Why?
|
Gene Expression Regulation, Enzymologic | 1 | 2017 | 168 | 0.140 |
Why?
|
Image Interpretation, Computer-Assisted | 1 | 2016 | 61 | 0.140 |
Why?
|
Gene Expression Regulation, Neoplastic | 3 | 2017 | 807 | 0.140 |
Why?
|
Soil | 1 | 2017 | 130 | 0.140 |
Why?
|
Neoplasm Staging | 1 | 2017 | 275 | 0.140 |
Why?
|
Fund Raising | 1 | 2015 | 1 | 0.130 |
Why?
|
Dogs | 1 | 2016 | 149 | 0.130 |
Why?
|
Bronchi | 1 | 2016 | 46 | 0.130 |
Why?
|
Imaging, Three-Dimensional | 1 | 2016 | 84 | 0.130 |
Why?
|
Sensitivity and Specificity | 2 | 2010 | 562 | 0.130 |
Why?
|
Signal Transduction | 3 | 2015 | 1908 | 0.130 |
Why?
|
Proteomics | 1 | 2018 | 325 | 0.130 |
Why?
|
Evolution, Molecular | 1 | 2017 | 268 | 0.130 |
Why?
|
Education, Medical, Graduate | 1 | 2015 | 55 | 0.130 |
Why?
|
Mice | 8 | 2015 | 5913 | 0.130 |
Why?
|
Neoplasm Proteins | 1 | 2017 | 213 | 0.130 |
Why?
|
Salinity | 1 | 2014 | 14 | 0.130 |
Why?
|
Registries | 1 | 2017 | 335 | 0.130 |
Why?
|
Diagnosis-Related Groups | 1 | 2014 | 13 | 0.120 |
Why?
|
Flocculation | 1 | 2014 | 6 | 0.120 |
Why?
|
Water Pollutants | 1 | 2014 | 17 | 0.120 |
Why?
|
Cell Proliferation | 3 | 2015 | 1198 | 0.120 |
Why?
|
Recreation | 1 | 2014 | 32 | 0.120 |
Why?
|
Biotransformation | 1 | 2014 | 67 | 0.120 |
Why?
|
Receptors, Tumor Necrosis Factor, Type II | 1 | 2014 | 12 | 0.120 |
Why?
|
Dose-Response Relationship, Radiation | 1 | 2014 | 36 | 0.120 |
Why?
|
Aged, 80 and over | 2 | 2018 | 2379 | 0.120 |
Why?
|
Base Sequence | 3 | 2013 | 997 | 0.120 |
Why?
|
Particle Size | 1 | 2014 | 215 | 0.120 |
Why?
|
Microscopy, Phase-Contrast | 1 | 2013 | 10 | 0.120 |
Why?
|
Whole-Body Irradiation | 2 | 2010 | 9 | 0.120 |
Why?
|
Quality Control | 1 | 2013 | 36 | 0.120 |
Why?
|
Mice, Inbred C3H | 2 | 2010 | 84 | 0.120 |
Why?
|
Recombination, Genetic | 1 | 2014 | 93 | 0.120 |
Why?
|
Mice, Inbred C57BL | 3 | 2017 | 1609 | 0.110 |
Why?
|
Escherichia coli O157 | 1 | 2013 | 16 | 0.110 |
Why?
|
Bacterial Proteins | 1 | 2018 | 540 | 0.110 |
Why?
|
Cell Survival | 2 | 2014 | 864 | 0.110 |
Why?
|
Blotting, Western | 2 | 2017 | 859 | 0.110 |
Why?
|
Lung | 1 | 2016 | 446 | 0.110 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2014 | 306 | 0.110 |
Why?
|
Enterococcus faecalis | 1 | 2013 | 39 | 0.110 |
Why?
|
United States | 1 | 2022 | 4223 | 0.110 |
Why?
|
Meibomian Glands | 1 | 2012 | 2 | 0.110 |
Why?
|
Eyelid Diseases | 1 | 2012 | 4 | 0.110 |
Why?
|
Micromonospora | 1 | 2012 | 1 | 0.110 |
Why?
|
Dry Eye Syndromes | 1 | 2012 | 5 | 0.110 |
Why?
|
Cell Cycle | 1 | 2014 | 326 | 0.100 |
Why?
|
Hyperthermia, Induced | 1 | 2012 | 17 | 0.100 |
Why?
|
Waste Products | 1 | 2012 | 3 | 0.100 |
Why?
|
Drug Resistance, Viral | 1 | 2012 | 63 | 0.100 |
Why?
|
Cellulases | 1 | 2012 | 2 | 0.100 |
Why?
|
Cellulase | 1 | 2012 | 5 | 0.100 |
Why?
|
Bacteria, Aerobic | 1 | 2012 | 7 | 0.100 |
Why?
|
Genome-Wide Association Study | 1 | 2014 | 333 | 0.100 |
Why?
|
Enzyme Assays | 1 | 2012 | 12 | 0.100 |
Why?
|
Ophthalmology | 1 | 2012 | 29 | 0.100 |
Why?
|
Communication | 1 | 2013 | 180 | 0.100 |
Why?
|
Mutation, Missense | 1 | 2012 | 83 | 0.100 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2014 | 356 | 0.100 |
Why?
|
Cattle | 2 | 2010 | 477 | 0.100 |
Why?
|
Brain Neoplasms | 1 | 2012 | 111 | 0.100 |
Why?
|
MicroRNAs | 1 | 2017 | 426 | 0.100 |
Why?
|
Combined Modality Therapy | 2 | 2018 | 148 | 0.100 |
Why?
|
Mammals | 1 | 2012 | 105 | 0.100 |
Why?
|
Cell Culture Techniques | 1 | 2012 | 142 | 0.100 |
Why?
|
Heme Oxygenase-1 | 1 | 2010 | 51 | 0.090 |
Why?
|
Luciferases | 1 | 2010 | 63 | 0.090 |
Why?
|
Immunoenzyme Techniques | 1 | 2010 | 108 | 0.090 |
Why?
|
Norfloxacin | 1 | 2010 | 1 | 0.090 |
Why?
|
Bacteriophage lambda | 1 | 2010 | 12 | 0.090 |
Why?
|
RNA, Archaeal | 1 | 2009 | 2 | 0.090 |
Why?
|
Embryo, Mammalian | 1 | 2010 | 153 | 0.090 |
Why?
|
Tetracyclines | 1 | 2009 | 2 | 0.090 |
Why?
|
Fluoroquinolones | 1 | 2009 | 7 | 0.090 |
Why?
|
Aging | 1 | 2015 | 664 | 0.090 |
Why?
|
Risk Factors | 2 | 2018 | 3562 | 0.090 |
Why?
|
DNA Probes | 1 | 2009 | 29 | 0.090 |
Why?
|
Radiation-Protective Agents | 1 | 2009 | 14 | 0.090 |
Why?
|
Vision, Binocular | 1 | 2009 | 9 | 0.090 |
Why?
|
Contrast Sensitivity | 1 | 2009 | 31 | 0.090 |
Why?
|
Gene Expression Regulation | 1 | 2015 | 1015 | 0.090 |
Why?
|
Ornithine Decarboxylase | 1 | 2009 | 10 | 0.090 |
Why?
|
Thymidine Kinase | 1 | 2009 | 7 | 0.080 |
Why?
|
Cross-Sectional Studies | 1 | 2017 | 2721 | 0.080 |
Why?
|
Viral Proteins | 1 | 2010 | 174 | 0.080 |
Why?
|
Age Factors | 3 | 2017 | 1033 | 0.080 |
Why?
|
Adult | 5 | 2018 | 11712 | 0.080 |
Why?
|
Deoxyguanine Nucleotides | 1 | 2008 | 3 | 0.080 |
Why?
|
Proteasome Endopeptidase Complex | 1 | 2009 | 114 | 0.080 |
Why?
|
Green Fluorescent Proteins | 1 | 2009 | 208 | 0.080 |
Why?
|
DNA-Directed DNA Polymerase | 1 | 2008 | 23 | 0.080 |
Why?
|
Neoplasms | 2 | 2015 | 1103 | 0.080 |
Why?
|
Mice, Knockout | 1 | 2010 | 933 | 0.080 |
Why?
|
Water Pollutants, Chemical | 1 | 2009 | 164 | 0.070 |
Why?
|
Cloning, Molecular | 1 | 2008 | 325 | 0.070 |
Why?
|
DNA, Mitochondrial | 1 | 2008 | 175 | 0.070 |
Why?
|
HIV-1 | 1 | 2012 | 706 | 0.070 |
Why?
|
RNA, Messenger | 1 | 2010 | 1207 | 0.070 |
Why?
|
Keratomileusis, Laser In Situ | 1 | 2004 | 4 | 0.060 |
Why?
|
Photorefractive Keratectomy | 1 | 2004 | 6 | 0.060 |
Why?
|
Lasers, Excimer | 1 | 2004 | 7 | 0.060 |
Why?
|
Oxidative Stress | 1 | 2010 | 938 | 0.060 |
Why?
|
Equipment Design | 1 | 2004 | 124 | 0.060 |
Why?
|
Cornea | 1 | 2004 | 58 | 0.060 |
Why?
|
Technology Transfer | 1 | 2003 | 1 | 0.060 |
Why?
|
Tomography, Emission-Computed | 1 | 2003 | 7 | 0.060 |
Why?
|
Public Health | 2 | 2018 | 372 | 0.060 |
Why?
|
Disease Progression | 2 | 2015 | 601 | 0.050 |
Why?
|
Adolescent | 2 | 2012 | 5363 | 0.050 |
Why?
|
Surface-Active Agents | 1 | 2021 | 41 | 0.050 |
Why?
|
Reproducibility of Results | 1 | 2004 | 935 | 0.050 |
Why?
|
Treatment Outcome | 2 | 2018 | 1369 | 0.050 |
Why?
|
Cell Line, Tumor | 3 | 2013 | 2231 | 0.050 |
Why?
|
Communicable Disease Control | 1 | 2021 | 32 | 0.050 |
Why?
|
Diarrhea | 1 | 2020 | 89 | 0.040 |
Why?
|
RNA, Viral | 1 | 2021 | 301 | 0.040 |
Why?
|
Bivalvia | 1 | 2019 | 21 | 0.040 |
Why?
|
Neoplasm, Residual | 1 | 2018 | 13 | 0.040 |
Why?
|
HIV Infections | 1 | 2012 | 2303 | 0.040 |
Why?
|
Retrospective Studies | 1 | 2004 | 2026 | 0.040 |
Why?
|
False Positive Reactions | 1 | 2017 | 26 | 0.040 |
Why?
|
Survival Rate | 1 | 2018 | 311 | 0.040 |
Why?
|
Time Factors | 2 | 2014 | 1742 | 0.040 |
Why?
|
Genomic Library | 1 | 2017 | 7 | 0.040 |
Why?
|
Bone Marrow | 1 | 2017 | 37 | 0.040 |
Why?
|
Survival Analysis | 1 | 2018 | 325 | 0.040 |
Why?
|
Principal Component Analysis | 1 | 2017 | 89 | 0.040 |
Why?
|
Genes, Bacterial | 1 | 2017 | 90 | 0.040 |
Why?
|
Environment | 1 | 2017 | 138 | 0.030 |
Why?
|
Ubiquitin-Protein Ligases | 1 | 2017 | 75 | 0.030 |
Why?
|
Genotype | 1 | 2018 | 730 | 0.030 |
Why?
|
Gift Giving | 1 | 2015 | 4 | 0.030 |
Why?
|
Risk Assessment | 1 | 2018 | 753 | 0.030 |
Why?
|
Computational Biology | 1 | 2017 | 293 | 0.030 |
Why?
|
Bystander Effect | 1 | 2014 | 11 | 0.030 |
Why?
|
Receptors, Tumor Necrosis Factor, Type I | 1 | 2014 | 21 | 0.030 |
Why?
|
Program Development | 1 | 2015 | 233 | 0.030 |
Why?
|
Transforming Growth Factor beta1 | 1 | 2015 | 93 | 0.030 |
Why?
|
Interleukin-1alpha | 1 | 2014 | 18 | 0.030 |
Why?
|
Gene Knockout Techniques | 1 | 2014 | 51 | 0.030 |
Why?
|
Program Evaluation | 1 | 2015 | 339 | 0.030 |
Why?
|
Insulin-Like Growth Factor I | 1 | 2014 | 70 | 0.030 |
Why?
|
Ligands | 1 | 2014 | 349 | 0.030 |
Why?
|
Histones | 1 | 2014 | 190 | 0.030 |
Why?
|
Oregon | 1 | 2012 | 43 | 0.030 |
Why?
|
Transduction, Genetic | 1 | 2012 | 19 | 0.030 |
Why?
|
Body Temperature | 1 | 2012 | 36 | 0.030 |
Why?
|
Cell Division | 1 | 2012 | 307 | 0.030 |
Why?
|
Gene Library | 1 | 2012 | 57 | 0.030 |
Why?
|
Cross-Over Studies | 1 | 2012 | 108 | 0.030 |
Why?
|
Intraocular Pressure | 1 | 2012 | 112 | 0.020 |
Why?
|
Animal Husbandry | 1 | 2010 | 18 | 0.020 |
Why?
|
Operon | 1 | 2010 | 44 | 0.020 |
Why?
|
RNA | 1 | 2012 | 241 | 0.020 |
Why?
|
Drug Evaluation, Preclinical | 1 | 2009 | 112 | 0.020 |
Why?
|
Immunosuppressive Agents | 1 | 2009 | 76 | 0.020 |
Why?
|
Models, Biological | 1 | 2012 | 677 | 0.020 |
Why?
|
Lymphocytes | 1 | 2009 | 118 | 0.020 |
Why?
|
Transplantation, Heterologous | 1 | 2009 | 90 | 0.020 |
Why?
|
DNA | 1 | 2012 | 574 | 0.020 |
Why?
|
Deoxyribonucleotides | 1 | 2008 | 11 | 0.020 |
Why?
|
Anti-HIV Agents | 1 | 2012 | 420 | 0.020 |
Why?
|
Mice, Nude | 1 | 2009 | 337 | 0.020 |
Why?
|
Prospective Studies | 1 | 2012 | 1378 | 0.020 |
Why?
|
Prevalence | 1 | 2012 | 1455 | 0.020 |
Why?
|
Rats, Wistar | 1 | 2008 | 233 | 0.020 |
Why?
|
Mitochondria, Heart | 1 | 2008 | 66 | 0.020 |
Why?
|
Research Design | 1 | 2009 | 313 | 0.020 |
Why?
|
Immunohistochemistry | 1 | 2009 | 893 | 0.020 |
Why?
|
Phenotype | 1 | 2009 | 689 | 0.020 |
Why?
|
Mitochondria | 1 | 2008 | 487 | 0.010 |
Why?
|
Technology, High-Cost | 1 | 2003 | 1 | 0.010 |
Why?
|
Rats | 1 | 2008 | 3483 | 0.010 |
Why?
|